Reference entry · PEG-conjugated synthetic MGF E-peptide
PEG-MGF
Also known as: Pegylated Mechano Growth Factor · PEGylated MGF E-peptide
- Class
- PEG-conjugated synthetic MGF E-peptide
- Primary targets (literature)
- Satellite cell / muscle repair literature (preclinical)
- Regulatory context
- Not FDA-approved. No human clinical trials completed. MGF analogs prohibited in sport (WADA).
Overview
PEG-MGF is a pegylated synthetic MGF E-domain peptide engineered for extended half-life. It does not exist endogenously; most systemic MGF animal data use pegylated rather than native peptide.
Mechanism in research literature
PEGylation reduces proteolytic clearance of the E-peptide scaffold, prolonging exposure in rodent repair models. Underlying biology derives from IGF-1Ec/MGF splice-variant research.
Common research focus areas
- Rodent muscle overload and injury repair endpoints
- Pharmacokinetic comparison vs. unpegylated MGF
- Distinction from IGF-1 LR3 and full-length IGF-1Ec
- MS confirmation of PEG mass and attachment site
Full literature roundup
Read the cited research summary
Pegylated synthetic MGF with extended half-life — a non-endogenous construct studied in muscle repair models. Preclinical-only evidence and strict identity requirements.
PEG-MGF research roundup · 4 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.